MX380122B - Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. - Google Patents

Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.

Info

Publication number
MX380122B
MX380122B MX2018005019A MX2018005019A MX380122B MX 380122 B MX380122 B MX 380122B MX 2018005019 A MX2018005019 A MX 2018005019A MX 2018005019 A MX2018005019 A MX 2018005019A MX 380122 B MX380122 B MX 380122B
Authority
MX
Mexico
Prior art keywords
preparation
benzofuran derivative
derivative
medicines
lymphoma
Prior art date
Application number
MX2018005019A
Other languages
English (en)
Other versions
MX2018005019A (es
Inventor
Biao Lu
Dong Liu
Mingxun He
Minsheng Zhang
Xiaodong Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018005019A publication Critical patent/MX2018005019A/es
Publication of MX380122B publication Critical patent/MX380122B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención se relaciona con un derivado de benzofurano, su método de preparación y un uso del mismo en medicina. En particular, la presente invención se relaciona con el derivado de benzofurano como se muestra con la fórmula general (I), el método de preparación del mismo, una composición farmacéutica que contiene el derivado, y usos del mismo como un inhibidor EZH2 y en la prevención y/o tratamiento de enfermedades como tumores y cánceres, etc., y en particular usos del mismo en la prevención y/o tratamiento del linforma de no Hodgkin, linfoma difuso de células B grandes, linfoma folicular y sarcoma sinovial, en donde las definiciones de los sustituyentes en la fórmula general (I) son las mismas que aquellas en la descripción. (ver Fórmula).
MX2018005019A 2015-11-19 2016-11-02 Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. MX380122B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510800975 2015-11-19
PCT/CN2016/104318 WO2017084494A1 (zh) 2015-11-19 2016-11-02 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2018005019A MX2018005019A (es) 2018-06-13
MX380122B true MX380122B (es) 2025-03-11

Family

ID=58717310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005019A MX380122B (es) 2015-11-19 2016-11-02 Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.

Country Status (20)

Country Link
US (2) US10759787B2 (es)
EP (1) EP3378859B1 (es)
JP (1) JP6828229B2 (es)
KR (2) KR20180081587A (es)
CN (1) CN107428742B (es)
AU (1) AU2016357900B2 (es)
BR (1) BR112018007876B1 (es)
DK (1) DK3378859T3 (es)
ES (1) ES2760510T3 (es)
HR (1) HRP20192209T1 (es)
HU (1) HUE047785T2 (es)
LT (1) LT3378859T (es)
MX (1) MX380122B (es)
PL (1) PL3378859T3 (es)
PT (1) PT3378859T (es)
RS (1) RS59763B1 (es)
RU (1) RU2727198C2 (es)
SI (1) SI3378859T1 (es)
TW (1) TWI718207B (es)
WO (1) WO2017084494A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
EP3626715A4 (en) * 2017-05-18 2021-03-24 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS
JP7295105B6 (ja) * 2017-11-10 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ベンゾフラン誘導体の製造方法
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
WO2020063863A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
EP3950682B1 (en) 2019-03-25 2026-02-11 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Preparation method for amide compounds and use thereof in medical field
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN113302185B (zh) * 2019-04-29 2024-04-09 上海和誉生物医药科技有限公司 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用
TW202108578A (zh) * 2019-05-10 2021-03-01 大陸商江蘇恒瑞醫藥股份有限公司 6-取代氨基苯并呋喃化合物的製備方法
CN110003187B (zh) * 2019-05-10 2021-11-05 南京工业大学 一种多氟烷基取代苯并呋喃类化合物及其制备方法
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
TW202126302A (zh) * 2019-09-30 2021-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Ezh2抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
WO2021063332A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
CN112870365A (zh) * 2019-11-29 2021-06-01 江苏恒瑞医药股份有限公司 Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
CN117956995A (zh) * 2021-08-30 2024-04-30 江苏恒瑞医药股份有限公司 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途
MX2024004579A (es) * 2021-10-15 2024-04-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Metodo de preparacion de derivado de benzofurano.
AU2023295387A1 (en) 2022-06-13 2025-01-09 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
KR20250023483A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 퀴놀론 bcl6 이작용성 분해제
US20250282742A1 (en) * 2024-03-08 2025-09-11 Automera PTE. LTD Benzofuran derivatives for targeting autophagy
WO2026021460A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 治疗前列腺癌的方法
WO2026128853A1 (en) * 2024-12-13 2026-06-18 Treeline Biosciences, Inc. Methods of treating cancer using an ezh2 inhibitor and a tricyclic quinolone heterobifunctional degrader of bcl6

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
EP2410171A1 (en) 2010-07-23 2012-01-25 Ewt Ip B.V. Wind turbine having a rotor with hub
SG180031A1 (en) 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9073924B2 (en) * 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
HK1214815A1 (zh) 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
PL3121175T3 (pl) 2014-03-17 2020-06-01 Daiichi Sankyo Company, Limited Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2

Also Published As

Publication number Publication date
AU2016357900A1 (en) 2018-05-24
JP2018538257A (ja) 2018-12-27
PL3378859T3 (pl) 2020-04-30
ES2760510T3 (es) 2020-05-14
AU2016357900B2 (en) 2020-09-17
LT3378859T (lt) 2020-01-27
PT3378859T (pt) 2019-12-11
MX2018005019A (es) 2018-06-13
CA3002436A1 (en) 2017-05-26
EP3378859A4 (en) 2018-09-26
RU2018119173A3 (es) 2020-02-13
EP3378859A1 (en) 2018-09-26
RU2727198C2 (ru) 2020-07-21
EP3378859B1 (en) 2019-10-30
JP6828229B2 (ja) 2021-02-10
BR112018007876A2 (pt) 2018-10-30
SI3378859T1 (sl) 2020-03-31
US11059811B2 (en) 2021-07-13
BR112018007876B1 (pt) 2023-10-17
KR20180081587A (ko) 2018-07-16
TW201718561A (zh) 2017-06-01
TWI718207B (zh) 2021-02-11
HK1243414A1 (zh) 2018-07-13
US20180327394A1 (en) 2018-11-15
CN107428742A (zh) 2017-12-01
CN107428742B (zh) 2020-05-08
DK3378859T3 (da) 2020-01-20
HUE047785T2 (hu) 2020-05-28
RU2018119173A (ru) 2019-12-19
WO2017084494A1 (zh) 2017-05-26
HRP20192209T1 (hr) 2020-07-24
RS59763B1 (sr) 2020-02-28
US10759787B2 (en) 2020-09-01
US20200354349A1 (en) 2020-11-12
KR20250028514A (ko) 2025-02-28

Similar Documents

Publication Publication Date Title
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017502246A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MY189761A (en) Quinazoline derivatives used to treat hiv
MX383213B (es) Inhibidores de tirosina-cinasas
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MX391221B (es) Compuestos y composiciones y usos de los mismos.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
TR201819805T4 (tr) Flavaglin türevleri̇.
MX386761B (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
HK1252245A1 (zh) 用於治疗癌症的核苷酸
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.